EPRX vs. URGN, QTTB, AVIR, VTYX, KMDA, ADCT, VNDA, NLTX, NKTR, and MRSN
Should you be buying Eupraxia Pharmaceuticals stock or one of its competitors? The main competitors of Eupraxia Pharmaceuticals include UroGen Pharma (URGN), Q32 Bio (QTTB), Atea Pharmaceuticals (AVIR), Ventyx Biosciences (VTYX), Kamada (KMDA), ADC Therapeutics (ADCT), Vanda Pharmaceuticals (VNDA), Neoleukin Therapeutics (NLTX), Nektar Therapeutics (NKTR), and Mersana Therapeutics (MRSN). These companies are all part of the "pharmaceutical preparations" industry.
UroGen Pharma (NASDAQ:URGN) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.
Eupraxia Pharmaceuticals has lower revenue, but higher earnings than UroGen Pharma.
UroGen Pharma received 353 more outperform votes than Eupraxia Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Eupraxia Pharmaceuticals an outperform vote while only 73.29% of users gave UroGen Pharma an outperform vote.
In the previous week, UroGen Pharma and UroGen Pharma both had 1 articles in the media. UroGen Pharma's average media sentiment score of 1.89 beat Eupraxia Pharmaceuticals' score of 1.87 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media.
91.3% of UroGen Pharma shares are owned by institutional investors. 11.1% of UroGen Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Eupraxia Pharmaceuticals' net margin of -123.74%.
UroGen Pharma presently has a consensus price target of $46.00, indicating a potential upside of 245.86%. Given Eupraxia Pharmaceuticals' higher probable upside, analysts clearly believe UroGen Pharma is more favorable than Eupraxia Pharmaceuticals.
Summary
UroGen Pharma and Eupraxia Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.
Get Eupraxia Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eupraxia Pharmaceuticals Competitors List
Related Companies and Tools
